Expression of TRAF1 in the Tumor Cells of HD and NHL
| Entity . | Case No. . | Percentage of Tumor Cells With TRAF1 Expression . | Intensity of TRAF1 Signal . | Kind of Associated Virus . |
|---|---|---|---|---|
| HD-MC | 1 | 90% | +++ | |
| 2 | 20% | + | ||
| 3 | 90% | +++ | EBV | |
| 4 | 90% | +++ | EBV | |
| 5 | 90% | +++ | EBV | |
| 6 | 90% | +++ | EBV | |
| 7 | 70% | +++ | EBV | |
| 8 | 80% | +++ | EBV | |
| 9 | 90% | +++ | EBV | |
| 10 | 90% | +++ | EBV | |
| 11 | 90% | +++ | EBV | |
| 12 | 80% | +++ | EBV | |
| HD-NS | 13 | 90% | +++ | |
| 14 | 80% | +++ | ||
| 15 | 80% | ++ | ||
| 16 | 90% | +++ | ||
| 17 | 90% | ++ | ||
| 18 | 100% | ++ | ||
| 19 | 90% | + | ||
| 20 | 90% | ++ | EBV | |
| 21 | 50% | ++ | EBV | |
| 22 | 80% | +++ | EBV | |
| 23 | 90% | +++ | EBV | |
| LPHD | 24 | 70% | ++ | |
| 25 | 60% | +++ | ||
| 26 | 70% | ++ | ||
| 27 | 90% | ++ | ||
| 28 | 50% | + | ||
| B-ALCL | 29 | 70% | ++ | |
| 30 | 90% | + | ||
| 31 | 10% | + | ||
| 32 | 90% | + | ||
| 33 | 80% | + | ||
| 34 | 50% | + | ||
| T-ALCL | 35 | 1% | + | |
| 36 | 0% | |||
| 37 | 0% | |||
| 38 | 20% | + | ||
| 39 | 30% | + | ||
| 0-ALCL | 40 | 70% | + | |
| 41 | 90% | + | ||
| B-CLL | 42 | <1% | + | |
| 43 | <1% | + | ||
| 44 | <1% | + | ||
| 45 | 1% | + | ||
| 46 | 0% | |||
| DLBCL | 47 | 20% | ++ | |
| 48 | 50% | + | HIV | |
| 49 | 20% | ++ | HIV | |
| 50 | 20% | + | HIV | |
| 51 | 30% | ++ | HIV | |
| 52 | 30% | ++ | HIV | |
| 53 | 1% | + | HIV, EBV | |
| 54 | 0% | HIV, EBV | ||
| 55 | 60% | + | HIV, EBV | |
| 56 | 5% | ++ | HIV, EBV | |
| 57 | 10% | ++ | HIV, EBV | |
| 58 | 2% | + | HIV, EBV | |
| 59 | 20% | ++ | HIV, EBV | |
| 60 | 10% | + | HIV, EBV | |
| 61 | 80% | +++ | EBV | |
| PLBLL | 62 | 0% | ||
| 63 | 0% | |||
| 64 | 0% | HIV, EBV | ||
| 65 | 0% | EBV | ||
| 66 | 20% | ++ | EBV | |
| Burk. | 67 | 20% | ++ | |
| 68 | 0% | EBV |
| Entity . | Case No. . | Percentage of Tumor Cells With TRAF1 Expression . | Intensity of TRAF1 Signal . | Kind of Associated Virus . |
|---|---|---|---|---|
| HD-MC | 1 | 90% | +++ | |
| 2 | 20% | + | ||
| 3 | 90% | +++ | EBV | |
| 4 | 90% | +++ | EBV | |
| 5 | 90% | +++ | EBV | |
| 6 | 90% | +++ | EBV | |
| 7 | 70% | +++ | EBV | |
| 8 | 80% | +++ | EBV | |
| 9 | 90% | +++ | EBV | |
| 10 | 90% | +++ | EBV | |
| 11 | 90% | +++ | EBV | |
| 12 | 80% | +++ | EBV | |
| HD-NS | 13 | 90% | +++ | |
| 14 | 80% | +++ | ||
| 15 | 80% | ++ | ||
| 16 | 90% | +++ | ||
| 17 | 90% | ++ | ||
| 18 | 100% | ++ | ||
| 19 | 90% | + | ||
| 20 | 90% | ++ | EBV | |
| 21 | 50% | ++ | EBV | |
| 22 | 80% | +++ | EBV | |
| 23 | 90% | +++ | EBV | |
| LPHD | 24 | 70% | ++ | |
| 25 | 60% | +++ | ||
| 26 | 70% | ++ | ||
| 27 | 90% | ++ | ||
| 28 | 50% | + | ||
| B-ALCL | 29 | 70% | ++ | |
| 30 | 90% | + | ||
| 31 | 10% | + | ||
| 32 | 90% | + | ||
| 33 | 80% | + | ||
| 34 | 50% | + | ||
| T-ALCL | 35 | 1% | + | |
| 36 | 0% | |||
| 37 | 0% | |||
| 38 | 20% | + | ||
| 39 | 30% | + | ||
| 0-ALCL | 40 | 70% | + | |
| 41 | 90% | + | ||
| B-CLL | 42 | <1% | + | |
| 43 | <1% | + | ||
| 44 | <1% | + | ||
| 45 | 1% | + | ||
| 46 | 0% | |||
| DLBCL | 47 | 20% | ++ | |
| 48 | 50% | + | HIV | |
| 49 | 20% | ++ | HIV | |
| 50 | 20% | + | HIV | |
| 51 | 30% | ++ | HIV | |
| 52 | 30% | ++ | HIV | |
| 53 | 1% | + | HIV, EBV | |
| 54 | 0% | HIV, EBV | ||
| 55 | 60% | + | HIV, EBV | |
| 56 | 5% | ++ | HIV, EBV | |
| 57 | 10% | ++ | HIV, EBV | |
| 58 | 2% | + | HIV, EBV | |
| 59 | 20% | ++ | HIV, EBV | |
| 60 | 10% | + | HIV, EBV | |
| 61 | 80% | +++ | EBV | |
| PLBLL | 62 | 0% | ||
| 63 | 0% | |||
| 64 | 0% | HIV, EBV | ||
| 65 | 0% | EBV | ||
| 66 | 20% | ++ | EBV | |
| Burk. | 67 | 20% | ++ | |
| 68 | 0% | EBV |
The hybridization signals were analyzed as described in Materials and Methods. Low intensity is indicated with +, medium intensity with ++, and strong intensity with +++.
Abbreviations: HD-MC, Hodgkin’s disease of mixed cellular subtype; HD-NS, Hodgkin’s disease of nodular sclerotic subtype; LPHD, lymphocyte-predominant Hodgkin’s disease; B-ALCL, anaplastic large-cell lymphoma with expression of B-cell markers; T-ALCL, anaplastic large-cell lymphoma with expression of T-cell markers; 0-ALCL, anaplastic large-cell lymphoma without expression of B- or T-cell markers; B-CLL, chronic lymphatic leukemia of B-cell type; DLBCL, diffuse large-cell lymphoma; PLBLL, plasmoblastic lymphoma; Burk., Burkitt’s lymphoma; EBV, Epstein-Barr virus; HIV, human immunodeficiency virus.